Boston Scientific (NYSE:BSX) Hits New 12-Month Low – What’s Next?

Boston Scientific Corporation (NYSE:BSX)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $71.83 and last traded at $72.48, with a volume of 2727219 shares trading hands. The stock had previously closed at $73.85.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BSX. Stifel Nicolaus dropped their target price on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Mizuho dropped their price objective on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Sanford C. Bernstein restated an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Finally, Royal Bank Of Canada cut their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Trading Down 1.2%

The company’s fifty day moving average is $86.46 and its 200-day moving average is $95.15. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $108.22 billion, a P/E ratio of 37.59, a P/E/G ratio of 1.05 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of BSX. BSN CAPITAL PARTNERS Ltd bought a new position in shares of Boston Scientific during the 4th quarter worth about $50,150,000. Employees Provident Fund Board bought a new position in Boston Scientific during the fourth quarter valued at about $203,533,000. EJMK Ventures LLC bought a new position in Boston Scientific during the fourth quarter valued at about $203,000. Reflection Asset Management acquired a new position in Boston Scientific in the 4th quarter valued at approximately $164,000. Finally, Tobam lifted its position in shares of Boston Scientific by 1,522.8% in the 4th quarter. Tobam now owns 11,376 shares of the medical equipment provider’s stock worth $1,085,000 after acquiring an additional 10,675 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.